Tag: CYDY

Options Updates, Fresh Plays

Options Updates:

We’re going to circle back today to highlight the performances of the options ideas we alerted on Friday morning. We selected the PRGS 07/17 $40 Calls as well as the SNX 07/17 $115-120 Calls.

In both cases, we have seen some solid moves, and with more than two weeks remaining until expiration, we’ll certainly continue to monitor their progress. Here were the figures they posted yesterday: 

PRGS 07/17 $40 Calls
$40: .20-.80 (+400%)
____

SNX 07/17 $115-120 Calls
$115: 4.64-9.50 (+180%)
$120: 2.74-7.50 (+214%)

_____

Fresh Ideas:
MU 07/02 $50-51.50 Calls
CAG 07/02 $33.50-34.50 Calls

Ideanomics, Inc. IDEX

Yesterday morning we suggested that our readers give their attention to IDEX in sessions to come, and we got some modest yet notable first day results.

The stock traded up from a low of 1.65 and hit 2.30 on the day, marking an intraday swing of 39%  It managed to maintain well over half of its advances, closing with strength at 2.09. This interests us more than enough to continue tracking its progress.

The company provided an update on its large electric vehicle order in a fresh PR this morning (>> Read PR)

Extended Watchlist:
CYDY, TPTW, PMCB, GOVX, PVDG,

Sustained Options Success

Options Updates
–
We try to make solid quick-strike options ideas for our readers and ourselves each and every morning. We generally do find at least some measure of success with that on a daily basis, and yesterday was no exception to that.

We signaled a range of bullish ideas for CAH, in addition to a bearish one for MAR which both turned in some decent gains on the day. A few of the longer term ideas we’ve been tracking saw increases as well, but we’ll come back to those at a later time.

For now, here are the moves made by yesterday’s targets so far: 

CAH Weekly $52.50-54 Calls
$52.50: .90-2.20 (+144%)
$53: .71-1.68 (+135%)
$53.50: .55-1.30 (+136%)
$54: .30-1.15 (+283%)

_____

MAR Weekly $86.50-85 Puts
$86.50: 3.98-5.24 (+32%)
$86: 3.40-5.15 (+51%)
$85.50: 4.10-5.00 (+22%)
$85: 2.80-4.50 (+61%)

More Fresh Ideas: 
MCY 06/19 $35-45 Calls
SPG Weekly $55-65 Calls
GWPH Weekly $110-115 Calls
NVAX 05/22 $38-40 Calls

Extended Watchlist:
BSGM, KTOV, NSPR, LUVU, VYST, CYDY, BTCS, GBTC

Sticking with SPY Puts

Solid Hits on the SPY

We try to formulate new options ideas for a given session as often as we can without forcing the issue, and on most days we produce at least one. Yesterday, we designated our sole set of new contracts to watch as the SPY Weekly $250-248 Puts, and thanks to a painful day for the markets, we were afforded the chance to score some pretty nice intraday gains.

Two out of three of those strike points translated into instant double-bag opportunities, with the third falling just 1% short of that mark, providing the following moves on the day: 

SPY Weekly $250-248 Puts
$250: 4.39-8.73 (+99%)
$249: 4.00-8.10 (+103%)
$248: 3.65-7.50 (+105%)
______

Fresh Ideas:
SPY Weekly $244-242 Puts
WBA Weekly $44-45 Calls
KMX Weekly $50-55 Calls


CytoDyn, Inc. CYDY

We began tracking CYDY on Tuesday morning, and in addition to making a nominal move on the chart, the company has also put out some coronavirus related press in the couple days. One of the company’s investigational drugs which is about to enter Phase 2b/3 trials, has demonstrated a promising level of  efficacy among severe COVID-19 patients.

The stock itself has run from 2.65-3.09 in the past couple of sessions, which marks a move of just 17% but we’re going to be interested to continue tracking its performance in light of the company’s announcements.

VANCOUVER, Washington, April 02, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the three-day effect of leronlimab in eight severely ill COVID-19 patients demonstrated a significant improvement in several important immunologic bio-markers.  Patient test data reveals improvement in cytokines, IL-6, and a trend toward the normalization of the CD4/CD8 ratio. (>>View Full PR)


Extended Watchlist:
GRYO, PNAT, ROTH, SOLI, CTYX, IPIX